Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C. Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment. Future Oncol. 2024 May 22;1-12. doi: 10.1080/14796694.2024.2348440
Furqan M, Karanth S, Goyal RK, Cai B, Rombi J, Davis KL, Caro N, Saliba T. Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study. Future Oncol. 2024 Apr 17. doi: 10.2217/fon-2023-1064
Paik PK, Goyal RK, Cai B, Price MA, Davis KL, Derrien Ansquer V, Caro N, Saliba TR. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib. Future Oncol. 2023 Jan;19(3):217-28. doi: 10.2217/fon-2022-1133
DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Nov;17(33):4635-47. doi: 10.2217/fon-2021-0742
Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. Future Oncol. 2021 Jul;17(21):2759-68.
Mansfield C, Myers K, Klein K, Patel J, Nakasato A, Ling YL, Tarhini AA. Risk tolerance in adjuvant and metastatic melanoma settings: a patient perspective study using the threshold technique. Future Oncol. 2021 Jun;17(17):2151-67. doi: 10.2217/fon-2020-1193
Tripathy D, Blum JL, Rocque GB, Bardia A, Karuturi MS, Cappelleri JC, Liu Y, Zhang Z, Davis KL, Wang Y. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. Future Oncol. 2020 Nov;16(31):2475-85. doi: 10.2217/fon-2020-0573
Vassilev ZP, Soriano Gabarro M, Kaye JA, Saltus CW, Riedel O, Scholle O, Mehtala J, Korhonen P, Garbe E, Zong J. Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. Future Oncol. 2020 Sep;16(25):1889-901. doi: 10.2217/fon-2020-0315
Damen JA, Pajouheshnia R, Heus P, Moons KGM, Reitsma JB, Scholten RJPM, Hooft L, Debray TPA. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 2019 Jun 13;17(1):109. doi: 10.1186/s12916-019-1340-7
Mansfield C, Ndife B, Chen J, Gallaher K, Ghate S. Patient preferences for treatment of metastatic melanoma. Future Oncol. 2019 Apr;15(11):1255-68. doi: 10.2217/fon-2018-0871
Darden C, Mitra D, McSorley D, Davis K, Band J, Iyer S. Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer. Future Oncol. 2019 Jan;15(2):141-50. doi: 10.2217/fon-2018-0531
Heus P, Damen JAAG, Pajouheshnia R, Scholten RJPM, Reitsma JB, Collins GS, Altman DG, Moons KGM, Hooft L. Poor reporting of multivariable prediction model studies: towards a targeted implementation strategy of the TRIPOD statement. BMC Med. 2018 Jul 19;16(1):120. doi: 10.1186/s12916-018-1099-2
Gutierrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Gitlin M, Robbins S. Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom. Bone. 2012 Sep 1;51(3):324-31.
Kiel DP, Grazette L, Siddhanti S, Daizadeh N, Wang A, Anthony MS, Christiansen C. Effect of denosumab on 3-year progression of aortic calcification in postmenopausal women with osteoporosis at high risk of cardiovascular events. Poster presented at the 37th European Symposium on Calcified Tissues Conference; June 2010. Glasgow, Scotland. [abstract] Bone. 2010 Jun; 47(Suppl 1):S69. doi: 10.1016/j.bone.2010.04.134